- Home
- LSF vs CELU Comparison
LSF vs CELU Comparison
Compare LSF & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | CELU |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | 123 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 50.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSF | CELU |
|---|---|---|
| Price | $2.26 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $6.00 |
| AVG Volume (30 Days) | ★ 88.3K | 60.6K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $40,578,000.00 |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.13 | $1.00 |
| 52 Week High | $8.96 | $4.35 |
Technical Indicators
Market Signals| Indicator | LSF | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 36.43 |
| Support Level | $2.13 | $1.62 |
| Resistance Level | $2.52 | $2.01 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 18.94 | 0.00 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.